Authors: Ward, KW Proksch, JW Azzarano, LM Salyers, KL McSurdy-Freed, JE Molnar, TM Levy, MA Smith, BR

Citation: Kw. Ward et al., SB-239063, a potent and selective inhibitor of p38 map kinase: Preclinicalpharmacokinetics and species-specific reversible isomerization, PHARM RES, 18(9), 2001, pp. 1336-1344

Authors: Ward, KW Proksch, JW Levy, MA Smith, BR

Citation: Kw. Ward et al., Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics, DRUG META D, 29(1), 2001, pp. 82-88

Authors: Ward, KW Proksch, JW Azzarano, LM Mumaw, JA Roethke, TJ Stelman, GJ Walsh, MJ Zeigler, KS McSurdy-Freed, JE Kehler, JR Chokshi, J Levy, MA Smith, BR

Citation: Kw. Ward et al., Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase, XENOBIOTICA, 31(11), 2001, pp. 783-797

Authors: Proksch, JW Gentry, WB Owens, SM

Citation: Jw. Proksch et al., The effect of rate of drug administration on the extent and time course ofphencyclidine distribution in rat brain, testis, and serum, DRUG META D, 28(7), 2000, pp. 742-747

Authors: Proksch, JW Gentry, WB Owens, SM

Citation: Jw. Proksch et al., Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats, J PHARM EXP, 292(3), 2000, pp. 831-837